NeuroCog Trials, Inc. announces that they have begun providing support for the cognitive outcomes of a new global Phase 3 clinical trial. This study investigates a genetic-based biomarker
Trial Press Release: NeuroCog Trials, Inc. announces support for the cognitive outcomes of a new global risk assignment algorithm to predict risk of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) within a five year period and to evaluate the efficacy of an investigational treatment in delaying the onset of MCI due to AD in cognitively normal individuals at high risk as determined by the risk assignment algorithm.
Richard Keefe, Ph.D., Founder and CEO of NeuroCog Trials, said, “We are tremendously excited to be a part of this trial. This program of research is at the crux of the latest developments in genetics, pharmacology, and neuroscience, advised by the world’s experts in cognition and Alzheimer’s Disease. We are honored that this prestigious group of academic and industry researchers has placed trust in NeuroCog Trials to provide support for the cognitive outcomes in this study. ”
The forthcoming trial will assess several thousand healthy people with a range of cognitive measures over the five-year course of the trial. Dr. Keefe added, “This is an innovative approach to the assessment of cognitive decline in people at risk for MCI. We applaud our colleagues in the pharmaceutical industry who are enthusiastic to adopt innovative new methodologies for assessing change in clinical trials. We also admire the raters and investigators who have demonstrated great excitement over being able to use the latest advances in assessment methodology.”